华熙生物(688363)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
开源证券 2024-01-07 买入
首创证券 2023-11-16 买入
  盈利预测
据华熙生物三季报分析:

  盈利能力维持稳定,主营获利能力有较大削弱

  成长能力有所削弱,经营业绩承受明显压力

  偿债能力维持稳定,偿还流动负债具有较好保障

  运营能力维持稳定,资金使用效率有所下降

  现金流能力有所削弱,现金满足投资的水平基本稳定

  财务数据
    截至第三季度实现净利润5.07亿元,每股收益1.07元。

    截至第三季度最新股东权益697418.16万元,未分配利润236955.27万元。

    截至第三季度最新总资产834956.35万元,负债137538.19万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入4,221,434,960.63,075,611,629.221,305,155,874.236,359,191,975.49
营业总成本3,695,744,556.372,625,933,511.091,120,138,044.485,322,193,479.66
营业利润611,164,707.27517,609,890.03243,117,465.391,136,313,779.01
利润总额610,427,459.6516,630,011.16241,748,595.191,136,112,001.75
净利润507,082,977.92421,561,907.33200,972,272.94961,380,206.07
其他综合收益7,791,296.7920,336,182.59-610,303.4514,809,397.55
综合收益总额514,874,274.71441,898,089.92200,361,969.49976,189,603.62
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计3,207,373,119.43,314,356,200.643,546,740,658.594,023,100,101.48
非流动资产合计5,142,190,416.595,053,965,982.744,912,829,135.134,658,654,249.09
资产总计8,349,563,535.998,368,322,183.388,459,569,793.728,681,754,350.57
流动负债合计1,109,576,607.321,215,612,339.561,282,695,782.351,644,038,583.06
非流动负债合计265,805,314.69244,295,056237,437,149.55354,727,689.26
负债合计1,375,381,922.011,459,907,395.561,520,132,931.91,998,766,272.32
归属于母公司股东权益合计6,926,287,411.686,856,249,478.176,883,737,855.426,633,775,580.33
股东权益合计6,974,181,613.986,908,414,787.826,939,436,861.826,682,988,078.25
负债和股东权益合计8,349,563,535.998,368,322,183.388,459,569,793.728,681,754,350.57
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计4,679,989,275.123,389,927,222.391,524,539,434.517,057,688,598.55
经营活动现金流出小计4,445,100,057.063,203,501,887.161,722,873,806.376,422,499,956.45
经营活动产生的现金流量净额234,889,218.06186,425,335.23-198,334,371.86635,188,642.1
投资活动现金流入小计1,470,210,836.631,338,726,143.891,047,194,091.43,510,592,288.1
投资活动现金流出小计1,848,807,483.971,522,454,912.3972,214,331.724,346,814,509.1
投资活动产生的现金流量净额-378,596,647.34-183,728,768.4174,979,759.68-836,222,221
筹资活动现金流入小计51,717,222.5851,717,222.5839,844,572.5227,326,698.37
筹资活动现金流出小计465,544,885.63437,053,896.6153,847,863.22397,483,363.39
筹资活动产生的现金流量净额-413,827,663.05-385,336,674.03-14,003,290.72-170,156,665.02
汇率变动对现金及现金等价物的影响7,198,775.6514,359,053.67467,979.1129,555,858.19
现金及现金等价物净增加额-550,336,316.68-368,281,053.54-136,889,923.79-341,634,385.73
期末现金及现金等价物余额692,958,984.28875,014,247.421,106,405,377.171,243,295,300.96
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润5.07亿元,每股收益1.07元。

    截至第三季度最新股东权益697418.16万元,未分配利润236955.27万元。

    截至第三季度最新总资产834956.35万元,负债137538.19万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入4,221,434,960.63,075,611,629.221,305,155,874.236,359,191,975.49
营业总成本3,695,744,556.372,625,933,511.091,120,138,044.485,322,193,479.66
营业利润611,164,707.27517,609,890.03243,117,465.391,136,313,779.01
利润总额610,427,459.6516,630,011.16241,748,595.191,136,112,001.75
净利润507,082,977.92421,561,907.33200,972,272.94961,380,206.07
其他综合收益7,791,296.7920,336,182.59-610,303.4514,809,397.55
综合收益总额514,874,274.71441,898,089.92200,361,969.49976,189,603.62
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计3,207,373,119.43,314,356,200.643,546,740,658.594,023,100,101.48
非流动资产合计5,142,190,416.595,053,965,982.744,912,829,135.134,658,654,249.09
资产总计8,349,563,535.998,368,322,183.388,459,569,793.728,681,754,350.57
流动负债合计1,109,576,607.321,215,612,339.561,282,695,782.351,644,038,583.06
非流动负债合计265,805,314.69244,295,056237,437,149.55354,727,689.26
负债合计1,375,381,922.011,459,907,395.561,520,132,931.91,998,766,272.32
归属于母公司股东权益合计6,926,287,411.686,856,249,478.176,883,737,855.426,633,775,580.33
股东权益合计6,974,181,613.986,908,414,787.826,939,436,861.826,682,988,078.25
负债和股东权益合计8,349,563,535.998,368,322,183.388,459,569,793.728,681,754,350.57
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计4,679,989,275.123,389,927,222.391,524,539,434.517,057,688,598.55
经营活动现金流出小计4,445,100,057.063,203,501,887.161,722,873,806.376,422,499,956.45
经营活动产生的现金流量净额234,889,218.06186,425,335.23-198,334,371.86635,188,642.1
投资活动现金流入小计1,470,210,836.631,338,726,143.891,047,194,091.43,510,592,288.1
投资活动现金流出小计1,848,807,483.971,522,454,912.3972,214,331.724,346,814,509.1
投资活动产生的现金流量净额-378,596,647.34-183,728,768.4174,979,759.68-836,222,221
筹资活动现金流入小计51,717,222.5851,717,222.5839,844,572.5227,326,698.37
筹资活动现金流出小计465,544,885.63437,053,896.6153,847,863.22397,483,363.39
筹资活动产生的现金流量净额-413,827,663.05-385,336,674.03-14,003,290.72-170,156,665.02
汇率变动对现金及现金等价物的影响7,198,775.6514,359,053.67467,979.1129,555,858.19
现金及现金等价物净增加额-550,336,316.68-368,281,053.54-136,889,923.79-341,634,385.73
期末现金及现金等价物余额692,958,984.28875,014,247.421,106,405,377.171,243,295,300.96
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
国寿成达(上海)健康产业股权投资中心(有限合伙)3443.3317.370.00
招商银行股份有限公司-华夏上证科创板50成份交易型开放式指数证券投资基金2004.2210.11841.09
北京国寿泰和一期股权投资合伙企业(有限合伙)582.722.94582.72
天津华杰海河医疗投资合伙企业(有限合伙)540.122.730.00
中国工商银行股份有限公司-易方达上证科创板50成份交易型开放式指数证券投资基金521.942.63135.25
WEST SUPREME LIMITED500.552.530.00
香港中央结算有限公司491.802.48-24.26
中国银行股份有限公司-招商国证生物医药指数分级证券投资基金308.051.55-6.90
Fortune Ace Investment Limited298.801.510.00
艾睿思(天津)医疗投资合伙企业(有限合伙)279.071.410.00
  主力控盘
  公司简介
华熙生物 所属地域: 山东省 涉及概念: 重组蛋白,生物医药,网络直播,沪股通,医美概念,融资融券
主营业务: 小容量注射剂、原料药、药用辅料、生物发酵原料、生物药品原料、透明质酸钠、食品原料、保健食品原料、保健食品、医疗器械产品、化妆品、食品、消毒卫生用品的开发、生产、销售;以及非公司自产精细化工原料、生物化工原料的进出口和批发。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
上市日期: 2019-11-06 每股净资产: 14.38元 每股收益: 1.07元 净利润: 5.14亿元 净利润增长率: -24.07%
营业收入: 42.21亿元 每股现金流: 0.49元 每股公积金: 7.95元 每股未分配利润: 4.92元 总股本: 4.82亿 流通股: 1.98亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心